Clinical Trial Detail

NCT ID NCT01801111
Title A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

Alectinib

Age Groups: adult

No variant requirements are available.